Pharmaceutical News
Neurocrine Biosciences has secured US Food and Drug Administration approval for Crenessity (crinecerfont). 17 December 2024
Eli Lilly has announced Phase III results for imlunestrant, its investigational oral selective estrogen receptor degrader (SERD), in breast cancer. 12 December 2024
GLP-1 receptor (GLP-1R) products have gained immense popularity in recent years, and four are currently approved in major markets to treat obesity—all of which are injectables. 2 December 2024
Exclusive
Company Spotlight
Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.
Most Read
10 December 2024
6 December 2024
2 December 2024
In Brief
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Mergers and Acquisitions
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
13 December 2024
13 December 2024
12 December 2024
7 December 2024
5 December 2024
29 November 2024
Editor's Pick
Boardroom
UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael Shih as chief executive (CEO) and to the board of directors, effective immediately. 16 December 2024
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze